Although the way pulmonologists both treat and define PFF has evolved, the clinician’s role in identifying when pulmonary fibrosis becomes progressive is still a critical aspect of care.
A Paradigm Shift in the Treatment of Scleroderma-Associated Interstitial Lung Disease
Kristin Highland, MD, discusses new potential pathways to treat scleroderma-associated interstitial lung disease.
Trial Results Offer New Hope for Scleroderma Patients
Results from a just-published landmark trial could lead to the first-ever approved drug for the treatment of systemic scleroderma-associated interstitial lung disease.